Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Apr 18;30(4):195–199. doi: 10.1002/clc.12

Cardiac manifestations of parasitic infections part 1: Overview and immunopathogenesis

Carlos Franco‐Paredes 1,4,✉, Nadine Rouphael 1, José Méndez 2, Erik Folch 1,5, Alfonso J Rodraíguez‐Morales 3, José Ignacio Santos 4, J W Hurst 2
PMCID: PMC6653029  PMID: 17443654

Abstract

Parasitic infections produce a wide spectrum of cardiac manifestations. They may involve various anatomic structures of the heart and are manifested clinically as myocarditis, cardiomyopathies, pericarditis, or pulmonary hypertension in many resource‐constrained settings. However, many parasitic infections involving the heart may also be currently diagnosed in developed countries due to growing worldwide travel, blood transfusions, and increasing numbers of immunosuppression states such as organ transplantation, use of immunosuppressive agents, or HIV/AIDS. Clinicians anywhere in the globe need to be aware of the potential cardiac manifestations of parasitic diseases. This is part one of a three‐part series discussing parasites of the heart. In this section, we provide a general overview and immunopathogenesis of parasitic infections of the heart. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: heart, parasites, Chagas disease, pericar‐ dium, myocardium

Full Text

The Full Text of this article is available as a PDF (283.6 KB).

REFERENCES

  • 1. Cubillos‐Garzón LA, Casas JP, Morillo CA, Bautista LE: Congestive heart failure in Latin America: The next epidemic. Am Heart J 2004; 147(3): 412–417. [DOI] [PubMed] [Google Scholar]
  • 2. Dias JC, Silveira AC, Schofield CJ: The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97: 603–611. [DOI] [PubMed] [Google Scholar]
  • 3. Barsoum RS: Parasitic infections in organ transplantation. Exp Clin Transplant 2004; 2(2): 258–267. [PubMed] [Google Scholar]
  • 4. Kumate J, Gutierrez G, Munoz O, Santos JI. Amibiasis In Manual de Infectologaía Clinica (16th ed.) (Eds. Kumate J, Gutierrez G, Muñoz O, Santos JI.), México D.F., México: Ed. Manual Moderno, pp. 201–211, 2001. [Google Scholar]
  • 5. Fauci AS: Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001; 32: 675–685. [DOI] [PubMed] [Google Scholar]
  • 6. Wakelin D: Helminths. Curr Opin Infect Dis 2000; 13: 465–469. [DOI] [PubMed] [Google Scholar]
  • 7. Kohl S, Pickering LK, Frankel LS, Yaeger RG: Reactivation of Chagas' disease during therapy of lymphocytic leukemia. Cancer 1982; 50: 827–828. [DOI] [PubMed] [Google Scholar]
  • 8. Leiguarda R, Roncoroni A, Taratuto AL, Jost L, Bertnier M, et al.: Acute CNS infection by Trypanosoma cruzi (Chagas' disease) in immunosuppressed patients. Neurology 1990; 40: 850–851. [DOI] [PubMed] [Google Scholar]
  • 9. Silva N, O'Bryan L, Medeiros L, Holand H, Suleiman J, et al.: Trypanosoma cruzi meningoencephalitis in HIV‐infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 342–349. [DOI] [PubMed] [Google Scholar]
  • 10. Rocha A, de Meneses AC, da Silva A, Ferreira MS, Nishioka SA, et al.: Pathology of patients with Chagas' disease and acquired immunodeficiency syndrome. Am J Trop Med Hyg 1994; 50: 261–268. [DOI] [PubMed] [Google Scholar]
  • 11. Kirchhoff LV: American trypanosomiasis (Chagas' disease)–A tropical disease now in the United States. N Engl J Med 1993; 329(9): 640–643. [DOI] [PubMed] [Google Scholar]
  • 12. Rassi A, Rassi A, Little WC: Chagas' heart disease. Clin Cardiol 2000; 23(12): 883–889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Eckert J, Desplazes P: Biological, epidemiological, and clinical aspects of Echinococcus, a zoonosis of increasing concern. Clin Microbiol Rev 2004; 17(1): 107–135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Ryning FW, McLeod R, Maddox JC, Hunt S, Remington JS: Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 1979; 90(1): 47–49. [DOI] [PubMed] [Google Scholar]
  • 15. Gallino A, Maggiorini M, Kiowski W, Martin X, Wunderli W, et al.: Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis 1996; 15(5): 389–393. [DOI] [PubMed] [Google Scholar]
  • 16. Wagner FM, Reichenspurner H, Uberfuhr P, Weiss M, Fingerle V, et al.: Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant 1994; 13(5): 916–918. [PubMed] [Google Scholar]
  • 17. de Medeiros BC, de Medeiros CR, Werner B, Loddo G, Pasquini R, et al.: Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases. Transpl Infect Dis 2001; 3(1): 24–28. [DOI] [PubMed] [Google Scholar]
  • 18. Leak D, Meghji M: Toxoplasmic infection in cardiac disease. Am J Cardiol 1979; 43(4): 841–849. [DOI] [PubMed] [Google Scholar]
  • 19. Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, et al.: Chagas' disease in patients with kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis 1999; 29(3): 561–567. [DOI] [PubMed] [Google Scholar]
  • 20. Khuroo MS: Hydatid disease: current status and recent advances. Ann Saudi Med 2002; 22(1–2): 56–64. [DOI] [PubMed] [Google Scholar]
  • 21. Sinha A, Grace C, Alston WK, Westenfeld F, Maguire JH: African trypanosomiasis in two travelers from the United States. Clin Infect Dis 1999; 29: 840. [DOI] [PubMed] [Google Scholar]
  • 22. Aucott JN, Ravdin JI: Amebiasis and “nonpathogenic” intestinal protozoa. Infect Dis Clin North Am 1993; 7: 467. [PubMed] [Google Scholar]
  • 23. Kirchhoff LV, Weiss LM, Wittner M, Tanowitz HB: Parasitic diseases of the heart. Front Biosci 2004; 9: 706–723. [DOI] [PubMed] [Google Scholar]
  • 24. Ibarra‐Perez C, Fernandez‐Diez J, Rodriguez‐Trujillo F: Myocardial cysticercosis: report of two cases with coexisting heart disease. South Med J 1972; 65(4): 484–486. [PubMed] [Google Scholar]
  • 25. Franco‐Paredes C, Santos JI: Parasitology resources on the World Wide Web: A powerful tool for infectious disease practitioners. Clin Infect Dis 2003; 37: 694–701. [DOI] [PubMed] [Google Scholar]
  • 26.Centers for Disease Control and Prevention. Chagas' disease After Organ Transplantation–United States 2001. MMWR 2002; 51(10): 210–212. [PubMed] [Google Scholar]
  • 27. Morel CM: Chagas disease, from discovery to control–and beyond: History, Myths and Lessons to take home. Mem Inst Oswaldo Cruz 1999; 94(Suppl 1): 3–16. [DOI] [PubMed] [Google Scholar]
  • 28. Herwaldt B: Leishmaniasis. Lancet 1999; 354: 1191–1199. [DOI] [PubMed] [Google Scholar]
  • 29. Tarleton RL: Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001; 31: 550–554. [DOI] [PubMed] [Google Scholar]
  • 30. Añez N, Crisante G, Maia da Silva F, Rojas A, Carrasco H, et al.: Predominance of lineage I among Trypanosoma cruzi isolates from Venezuelan patients with different clinical profiles of acute Chagas' disease. Trop Med Intern Health 2004; 9(12): 1319–1326. [DOI] [PubMed] [Google Scholar]
  • 31. Rivera J, Hillis DL, Levine BD: Reactivation of cardiac Chagas' disease in acquire immune deficiency syndrome. Am J Cardiol 2004; 94: 1102–1103. [DOI] [PubMed] [Google Scholar]
  • 32. Bestetti RB: Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet 1996; 347: 913–914. [DOI] [PubMed] [Google Scholar]
  • 33. Añez N, Carrasco H, Parada H, Crisante G, Rojas A, et al.: Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 1999; 60(5): 726–732. [DOI] [PubMed] [Google Scholar]
  • 34. Urbina JA, Payares G, Sanoja C, Molina J, Lira R, et al.: Parasitological cure of acute and chronic experimental Chagas disease using the long‐acting experimental triazole TAK‐187. Activity against drug‐resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003; 21(1): 39–48. [DOI] [PubMed] [Google Scholar]
  • 35. Krylov GG: Cardiac syndrome in opisthorchiasis. Med Parazitol 2004; 3: 27–29. [PubMed] [Google Scholar]
  • 36. Lages‐Sila E, Crema E, Ramirez LE, Macedo AM, Pena SD, et al.: Relationship between Trypanosoma cruzi and human chagasic megaesophagus: blood and tissue parasitism. Am J Trop Med Hyg 2001; 65(5): 435–441. [DOI] [PubMed] [Google Scholar]
  • 37. Brandariz S, Schijman A, Vigliano CA, Viotti R, Beldjord CL: Detection of parasite DNA in Chagas' Heart disease. Lancet 1995; 346: 1370–1371. [DOI] [PubMed] [Google Scholar]
  • 38. Norris KA: Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote‐specific complement regulatory protein cDNA confers complement resistance. Infect Immun 1998; 66: 2460–2465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Sibley LD, Andrews NW: Cell invasion by un‐palatable parasites. Traffic 2000; 1: 100–106. [DOI] [PubMed] [Google Scholar]
  • 40. Mordue DG, Desai N, Dustin M, Sibley LD: Invasion by Toxoplasma gondii establishes a moving junction that selectively excludes host cell plasma membrane proteins on the basis of their membrane anchoring. J Exp Med 1999; 190: 1783–1792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Sacks D, Sher D: Evasion of innate immunity by parasitic protozoa. Nat Med 2002; 3(11): 1041–1047. [DOI] [PubMed] [Google Scholar]
  • 42. Jautzke G, Sell M, Thalmann U, Janitschke K, Gottschalk J, et al.: Extracerebral toxoplasmosis in AIDS. Histological and immunohistological findings based on 80 autopsy cases. Pathol Res Pract 1993; 189(4): 428–436. [DOI] [PubMed] [Google Scholar]
  • 43. Hoffman P, Bernard E, Michiels JF, Thyss A, Le Fichoux Y, et al.: Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS). Pathol Res Pract 1993; 189(8): 894–901. [DOI] [PubMed] [Google Scholar]
  • 44. Sahasrabudhe NS, Jadhav MV, Deshmukh SD, Holla VV: Pathology of Toxoplasma myocarditis in acquired immunodeficiency syndrome. Indian J Pathol Microbiol 2003; 46(4): 649–651. [PubMed] [Google Scholar]
  • 45. Lobos E, Nutman T, Hothersall JS, Moncada S: Elevated immunoglobulin E against recombinant Brugia malayi g‐glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity. Infect Immun 2003; 71: 747–753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Di Noia J, Buscaglia CA, De Marchi CR, Almeida JC, Frasch AC: A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage. J Exp Med 2002; 195: 401–413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Breniere SF, Bosseno MF, Telleria J, Bastrenta B, Yacsik N, et al.: Different behavior of two Trypanosoma cruzi major clones: transmission and circulation in young Bolivian patients. Exp Parasitol 1998; 89: 285–295. [DOI] [PubMed] [Google Scholar]
  • 48. Torrico F, Heremans H, Rivera MT, Van ME, Billiau A, et al.: Endogenous INF‐gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol 1991; 146: 3626–3632. [PubMed] [Google Scholar]
  • 49. Monteon‐Padilla V, Hernandez‐Becerril N, Ballinas‐Verdugo MA, Aranda‐Fraustro A, Reyes PA: Persistente of Trypanosoma cruzi in chronic chagasic cardiopathy patients. Arch Med Res 2001; 32: 39–43. [DOI] [PubMed] [Google Scholar]
  • 50. Lannes‐Vieira J: Trypanosoma cruzi‐elicited CD8+ T cell‐mediated myocarditis: chemokine receptors and adhesion molecules as potential therapeutic targets to control chronic inflammation? Mem Inst Oswaldo Cruz 2003; 98(3): 299–304. [DOI] [PubMed] [Google Scholar]
  • 51. Braga MS, Lauria‐Pires L, Arganaraz ER, Nascimento RJ, Teixeira AR: Persistent infections in chronic Chagas' disease patients treated with anti‐ Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000; 42(3): 157–161. [DOI] [PubMed] [Google Scholar]
  • 52. Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FQ: Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi in mice by inducing nitric oxide production in infected INF‐g‐activated macrophages. Infect Immun 1995; 63: 4862–4867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, et al.: IL‐12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 1996; 64: 1961–1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Pinge‐Filho P, tadokoro CE, Abrahamsohn IA: Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection. Cell Immunol 1999; 193: 90–98. [DOI] [PubMed] [Google Scholar]
  • 55. Urbina JA, Concepcion JL, Montalvetti A, Rodriguez JB, Docampo R: Mechanism of action of 4‐phenoxyphenoxyethyl thiocyanate (WC‐9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob Agents Chemother 2003; 47(6): 2047–2050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Vinhaes MC, Schofield CJ: Trypanosomiasis control: surmounting diminising returns. Trends Parasitol 2003; 19: 112–113. [DOI] [PubMed] [Google Scholar]
  • 57. Brener Z, Gazzinelli RT: Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' Disease. Int Arch Allergy Appl Immunol 1997; 114: 103–110. [DOI] [PubMed] [Google Scholar]
  • 58. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, et al.: CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi . J Infect Dis 2005; 191(4): 627–636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Buscaglia CA, Di Noia JM: Trypanosoma cruzi clonal diversity and the epidemiology of Chagas' disease. Microbes Infect 2003; 5: 419–427. [DOI] [PubMed] [Google Scholar]
  • 60. Anez N, Crisante G, Rojas A, Diaz N, Anez‐Rojas N, et al.: La cara oculta de la enfermedad de Chagas en Venezuela. Bol. Malar. Sal. Ambi. 2003; XLIII(2): 45–57. [Google Scholar]
  • 61. Urbina JA: Parasitological cure of Chagas Disease: Is it possible? Is it relevant? Mem Inst Oswaldo Cruz 1999; 94(Suppl 1): 349–355. [DOI] [PubMed] [Google Scholar]
  • 62. de Cleva R, Herman P, Pugliese V, Zilberstein B, Saad WA, et al.: Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis—prospective study. Hepatogastroenterol 2003; 50(54): 2028–2030. [PubMed] [Google Scholar]
  • 63. Mangoud AM, Morsy TA, Ramadan ME, Makled KM, Mostafa SM: The pathology of the heart and lung in Syrian golden hamsters experimentally infected with Leishmani d. Infantum on top of pre‐existing Schistosoma mansoni infection. J Egypt Soc Parasitol 1998; 28(2): 395–402. [PubMed] [Google Scholar]
  • 64. Denie C, Vachiery F, Elman A, Soupison T, Gadano A, et al.: Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996; 16(5): 309–312. [DOI] [PubMed] [Google Scholar]
  • 65. Berger PB, Duffy J, Reeder GS, Karon BL, Edwards WD: Restrictive cardiomyopathy associated with the eosinophilia‐myalgia syndrome. Mayo Clin Proc 1994; 69: 162–165. [DOI] [PubMed] [Google Scholar]
  • 66. Olsen EG, Spry CJ: Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis 1985; 27: 241–254. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES